AD/PD™ Neuro Talks – Early Alzheimer’s: Biomarkers in Practice

In collaboration with Eisai, AD/PD™ presents a new expert interview series exploring the clinical and scientific developments transforming the future of Early Alzheimer’s Disease diagnosis and care.

Recorded onsite at AD/PD™ 2026, these relaxed and insightful conversations bring together leading international experts and host Dr. Samuel Lockhart to discuss the evolving role of blood-based biomarkers (BBMs) across clinical practice and research.

About the Series

This four-episode series examines key topics surrounding Early Alzheimer’s Disease and BBM implementation through expert-led conversations designed for healthcare professionals involved in neurology, dementia care, and cognitive disorders.

Each episode offers practical insights, current evidence, and discussion around the opportunities and challenges facing clinicians today.

Meet Your Host

Dr. Samuel Lockhart is Sr. Scientific Director at Perceptive and Adjunct Associate Professor at Wake Forest School of Medicine. His work focuses on neurodegenerative diseases, biomarker development, and advancing innovative approaches to Alzheimer’s disease research and clinical care.

Featured Speakers

• Dr. Simon Ducharme – Neuropsychiatrist and clinician-scientist at The Neuro and the Douglas Mental Health University Institute
• Dr. Noa Bregman – Director of the Cognitive Neurology Unit at Tel Aviv Medical Center, Gray School of Medicine, Faculty of Medical & Health Sciences, Tel Aviv University
• Dr. Suzanne Schindler – Associate Professor at Washington University School of Medicine in St. Louis
• Dr. Sid O’Bryant – Principal Investigator of the Health & Aging Study, University of North Texas Health Science Center
• Prof. Charlotte Teunissen – Professor in Neurochemistry, Department of Laboratory Medicine, Amsterdam UMC

🎙️ Episode 1: Preclinical AD Within the AD Continuum

Featured Speaker: Simon Ducharme, MD, FRCP(C)

In this first episode we discuss the growing importance of understanding preclinical Alzheimer’s disease within the broader AD continuum.

The conversation explores evolving definitions, clinical implications, and how advances in biomarkers and early identification may influence future approaches to diagnosis and care.

Discussion Highlights

• Understanding preclinical AD
• Defining the AD continuum
• Clinical implications of earlier detection
• Emerging perspectives in research and practice

Honorarium provided for participation in this activity.